IOL Chemicals & Pharmaceuticals Intrinsic Value
IOL Chemicals & Pharmaceuticals (IOLCP) median intrinsic value is ₹406.30 from 10 valuation models (range ₹61–₹508), vs current price ₹203.15 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit IOL Chemicals & Pharmaceutical screener.
IOLCP Valuation Methods Summary — DCF, Graham Number & P/E
IOL Chemicals & Pharmaceuticals intrinsic value across 10 models vs current price ₹203.15 — upside/downside and value range per method. See IOLCP book value to compare market price against book value per share.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹159.28 | ₹127.42 - ₹191.14 | -21.6% | EPS: ₹7.24, Sector P/E: 22x |
| Book Value Method | asset | ₹507.88 | ₹457.09 - ₹558.67 | +150.0% | Book Value/Share: ₹304.92, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹406.30 | ₹365.67 - ₹446.93 | +100.0% | Revenue/Share: ₹421.02, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹406.30 | ₹365.67 - ₹446.93 | +100.0% | EBITDA: ₹376.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹492.68 | ₹394.14 - ₹591.22 | +142.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹60.95 | ₹54.86 - ₹67.05 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹111.86 | ₹100.67 - ₹123.05 | -44.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹406.30 | ₹365.67 - ₹446.93 | +100.0% | ROE: 11.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹222.87 | ₹200.58 - ₹245.16 | +9.7% | EPS: ₹7.24, BVPS: ₹304.92 |
| Dividend Yield Method | dividend | ₹60.95 | ₹54.86 - ₹67.05 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
IOLCP Intrinsic Value vs Market Price — All Valuation Models
IOL Chemicals & Pharmaceuticals fair value range ₹61–₹508 vs current market price ₹203.15 across 10 valuation models. Check IOLCP company valuation to track the company's total market size over time.
IOLCP Intrinsic Value Analysis — Undervalued or Overvalued?
IOL Chemicals & Pharmaceuticals median intrinsic value ₹406.30, current price ₹203.15 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of IOLCP?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of IOL Chemicals & Pharmaceuticals (IOLCP) is ₹406.30 (median value). With the current market price of ₹203.15, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹60.95 to ₹507.88, indicating ₹60.95 - ₹507.88.
Is IOLCP undervalued or overvalued?
Based on our multi-method analysis, IOL Chemicals & Pharmaceuticals (IOLCP) appears to be trading below calculated value by approximately 100.0%.
IOLCP Financial Health — Key Ratios vs Industry Benchmarks
IOL Chemicals & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.53 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.96x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
IOLCP Cash Flow Quality — Operating & Free Cash Flow
IOL Chemicals & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹214 Cr | ₹115 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹179 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹290 Cr | ₹195 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹122 Cr | ₹62 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹93 Cr | ₹33 Cr | Positive Free Cash Flow | 7/10 |